Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.
about
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerHCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell linesHigh-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines.Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomasSTAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.Epidermal growth factor receptor gene copy number aberration at the primary tumour is significantly associated with extracapsular spread in oral cancer.STAT3 signaling: anticancer strategies and challenges.Response to combined molecular targeting: defining the role of P-STAT3.Unique FISH patterns associated with cancer progression of oral dysplasia.Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.Production of Uniform 3D Microtumors in Hydrogel Microwell Arrays for Measurement of Viability, Morphology, and Signaling Pathway ActivationOverexpression of Bcl-2 induces STAT-3 activation via an increase in mitochondrial superoxide.Clinicopathological significance of STAT4 in hepatocellular carcinoma and its effect on cell growth and apoptosis.Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines.Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer.EGFR tyrosine kinase inhibitors differentially affect autophagy in head and neck squamous cell carcinoma.High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines.Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
P2860
Q26852215-6AB19C68-92B4-4673-BA5F-3DABAAFB3685Q30278790-4289655E-B440-435E-ADFF-DE0DC86286DEQ30408290-10FA43DF-FE97-4A89-BE30-E5974822D395Q30655673-75D76325-0279-48BC-BF7C-F22CC88E55FCQ33391825-B83E507A-7910-4959-889F-5344B3067111Q33575439-E9CF3A17-5E48-47B9-82DF-3A141018115CQ34518357-6F296CAC-CFF2-4F53-B001-2F45F6207829Q34621876-9E52D392-DD27-4749-B553-26CAE5FAFDE6Q34715455-9F611FAE-C0C1-4469-B647-4B0E07EFCDD3Q35146581-2B69A464-E2B7-4E3C-9431-1E93C6D4002DQ35596552-FBF0BD4D-5995-4F8D-BB26-182FC81B5DF9Q36109785-38DE6292-750E-4C22-A05B-208F37EDE029Q36297745-E8B232E7-33C6-4254-B2EC-FAD5018DFFC1Q36544047-A304A99C-26A5-4201-B0CB-18F1805141D3Q36729248-BE8E6506-957E-4024-8512-D246FEEBCCC1Q39423669-E05577B0-7E73-4CDE-830A-254637761185Q39524625-36025A60-C7AD-4659-B7BA-861C54EA91E7Q39709920-2DDF0B8A-8EEB-487A-A601-41479693EEC9Q45056156-FFE82CE4-D7C4-4EA6-8797-0418CED90797Q45071297-3D111738-5E63-49B3-92F9-7CA6A958D0E4Q47350013-A45C0478-5B7C-4250-9320-0D4D56E5931AQ53258023-5222BF0E-6E24-4FCA-9BAC-4DDF2334E756
P2860
Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Improving Response Rates to EG ...... Treatment with Src Inhibitors.
@en
Improving Response Rates to EG ...... Treatment with Src Inhibitors.
@nl
type
label
Improving Response Rates to EG ...... Treatment with Src Inhibitors.
@en
Improving Response Rates to EG ...... Treatment with Src Inhibitors.
@nl
prefLabel
Improving Response Rates to EG ...... Treatment with Src Inhibitors.
@en
Improving Response Rates to EG ...... Treatment with Src Inhibitors.
@nl
P2860
P356
P1433
P1476
Improving Response Rates to EG ...... Treatment with Src Inhibitors.
@en
P2093
Ann Marie Egloff
Jennifer Rubin Grandis
P2860
P304
P356
10.1155/2009/896407
P577
2009-07-14T00:00:00Z